Our pipeline is rich with opportunity

OncoResponse antibodies to key targets reverse and relieve immunosuppression in the tumor microenvironment to enhance responses from immunotherapy to greater cures.  OR2805 reprograms M2-like TAMs leading to increased adaptive T-cell activation and proliferation.

timeline of three antibodies in various stages of preclinical development advancement

                        graph indicating OR2805 superior anti-PD-1